childhood cancer research; commission

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

childhood cancer research; commission

HB2082 - 572R - Senate Fact Sheet Assigned to HHS������������������������������������������������������������������������������������������������ AS PASSED BY COMMITTEE ARIZONA STATE SENATE Fifty-Seventh Legislature, Second Regular Session AMENDED FACT SHEET FOR h.b.

What This Bill Does

• HB2082 - 572R - Senate Fact Sheet Assigned to HHS������������������������������������������������������������������������������������������������ AS PASSED BY COMMITTEE ARIZONA STATE SENATE Fifty-Seventh Legislature, Second Regular Session AMENDED FACT SHEET FOR h.b.
• 2082 childhood cancer research; commission Purpose Establishes the Childhood Cancer and Rare Childhood Disease Research Commission (Commission) consisting of monies allocated from the Childhood Cancer and Rare Childhood Disease Research Fund (Fund).
• Outlines Commission grant qualifications and membership.
• Background The Fund consists of monies received from fees collected from the issuance of Childhood Cancer Research special plates and is administered by the Director of the Department of Health Services (DHS).

Limits and Unknowns

• This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Official Summary Text

HB2082 - 572R - Senate Fact Sheet

Assigned to
HHS������������������������������������������������������������������������������������������������ AS
PASSED BY COMMITTEE

ARIZONA STATE SENATE

Fifty-Seventh
Legislature, Second Regular Session

AMENDED

FACT SHEET FOR
h.b. 2082

childhood
cancer research; commission

Purpose

Establishes the
Childhood Cancer and Rare Childhood Disease Research Commission (Commission)
consisting of monies allocated from the Childhood Cancer and Rare Childhood Disease
Research Fund (Fund). Outlines Commission grant qualifications and membership.

Background

The Fund
consists of monies received from fees collected from the issuance of Childhood
Cancer Research special plates and is administered by the Director of the
Department of Health Services (DHS). Monies in the Fund are continuously
appropriated and annually distributed. The Director of DHS must allocate monies
from the Fund to Arizona health care providers and research institutions that
are engaged in phase I clinical trials relating to research on pediatric cancer
or other rare pediatric diseases. Allocated monies may be used in a
collaborative study or research program with other, out-of-state facilities.
Nonprofit organizations receiving money from the Fund must use the monies for
the prescribed purposes, even if the monies are aggregated with other monies.
Monies in the Fund are exempt from lapsing (
A.R.S.
� 36-121
).

There is no
anticipated fiscal impact to the state General Fund associated with this
legislation.

Provisions

1.

Establishes
the Commission, consisting of members appointed by the Director of DHS, including
at least the following:

a)

one member who is a survivor of childhood cancer or a caregiver to
individuals who have childhood cancer;

b)

one member who is a survivor of a rare childhood disease or the
caregiver to individuals who have rare childhood diseases;

c)

four health professionals who practice in the field of pediatric cancer
or rare childhood diseases; and

d)

one
representative of a nationwide pediatric cancer advocacy nonprofit
organization.

2.

Requires Commission members to serve five-year terms and annually elect
a chairperson from the membership.

3.

Specifies that Commission members are not eligible to receive
compensation but are eligible for reimbursement of expenses.

4.

Requires
the Commission to:

a)

establish criteria for the clinical trials that qualify to receive
grants;

b)

oversee the application process and review applications for the clinical
trial research grants to assist the Director of DHS in selecting the most
credible clinical trials to be awarded grants; and

c)

ensure
that all Commission meetings are open to the public and allow for public
testimony.

5.

Requires the Director of DHS to award grants to Arizona nonprofit health
care providers and research institutions that are engaged in clinical trials
relating to research on pediatric cancer or other rare pediatric diseases.

6.

Allows monies awarded by grants to be used in a collaborative study or
research program with other, out-of-state facilities.

7.

Requires nonprofit organizations that receive grant monies to use the
monies for the outlined purposes, even if the monies are aggregated with other
monies.

8.

Requires Commission members to recuse themselves from discussing and
voting on any matter in which the members have a conflict of interest.

9.

Allows the Director of DHS and other Director-appointed DHS staff
members to act as members of the Commission on any grant application if grant
member recusals due to conflicts of interest cause the Commission to lack
quorum to take official action.

10.

Requires the Commission,
beginning August 1, 2027, to submit an annual report to the Appropriations and
Health and Human Services Committees of the Senate and House of
Representatives, or their successor committees, detailing the:

a)

number, amounts and recipients of the awarded grants;

b)

resulting research; and

c)

any
other relevant information.

11.

Adds,
to the funding sources available for the Fund, legislative appropriations,
gifts, donations and federal grants.

12.

Requires
the Director of DHS, subject to a legislative appropriation, federal grants or
a combination of both totaling at least $5,000,000 to allocate monies from the
Fund for grants awarded by the Commission.

13.

Allows
the Director of DHS to use up to four percent of the amount appropriated or
granted to cover administrative costs, unless otherwise specified by the
associated federal grant contract.

14.

Requires
the Director of DHS, if DHS does not receive at least $5,000,000 in additional
legislative appropriations, federal grants or a combination thereof to allocate
monies from the Fund to health care providers and research institutions in
Arizona that are nonprofit organizations and that are engaged in clinical
trials relating to research on pediatric cancer or other rare pediatric
diseases.

15.

Allows
monies allocated by the Director of DHS to be used in a collaborative study or
research program with other, out-of-state facilities.

16.

Requires nonprofit
organizations that receive grant monies to use the monies as specified, even if
the monies are aggregated with other monies.

17.

Makes
technical and conforming changes.

18.

Becomes
effective on the general effective date.

Amendments Adopted by
Committee

1.

Subjects allocations of monies from the Fund to the Commission on the
Fund receiving legislative appropriations, the award of federal grants or a
combination thereof totaling at least $5,000,000 for the purposes of childhood
cancer and rare childhood research.

2.

Specifies that the Director of DHS may use up to four percent of the
amounts appropriated or granted for administrative costs.

3.

Requires, if DHS does not meet the funding requirement, the Director of
DHS to allocate monies from the Fund to prescribed nonprofit organizations for the
outlined purposes.

4.

Outlines permissible uses for monies allocated by the Director of DHS.

5.

Requires the Director of DHS, rather than the Commission, to award
grants as outlined.

6.

Requires
the Commission to:

a)

establish
criteria for clinical trials to qualify for grants;

b)

oversee
and review applications to assist the Director in selection; and

c)

ensure
that all Commission meetings are open to the public and allow for public
testimony.

7.

Removes the requirement that the annual report include the Commission's
return on investment.

8.

Makes technical and conforming changes.

House Action
����������������������������������������������������������
Senate
Action

HHS��������������� 1/22/26����� DP���� 12-0-0-0�������������� HHS��������������� 3/11/26����� DPA������ 7-0-0

3
rd
Read��������� 2/25/26���������������� 44-9-7

Prepared by Senate Research

March 13, 2026

MM/SDR/hk

Current Bill Text

Chapter 0079 - 572R - S Ver of HB2082

Senate Engrossed
House Bill

childhood cancer
research; commission

State of Arizona

House of Representatives

Fifty-seventh Legislature

Second Regular Session

2026

CHAPTER 79

HOUSE BILL 2082

AN
ACT

amending section 36-121, Arizona Revised
Statutes; amending title 36, chapter 1, article 1, Arizona Revised Statutes, by
adding section 36-121.01; relating to the department of health services.

(TEXT OF BILL BEGINS ON NEXT PAGE)

Be it enacted by the Legislature of the State of Arizona:

Section 1. Section 36-121, Arizona Revised
Statutes, is amended to read:

START_STATUTE
36-121.

Childhood cancer and rare childhood disease research fund

A. The childhood cancer and rare childhood disease
research fund is established consisting of monies received pursuant to section
28-2442
, legislative appropriations, gifts, donations and
federal grants
. The director shall administer the fund.� Not
more than ten
per cent
percent
of
monies deposited in the fund annually shall be used for the cost of
administering the fund.� The first
thirty-two thousand dollars

$32,000
received
pursuant to section
28-2442
shall be reimbursed to the person or entity that paid the
implementation fee. Monies in the fund are continuously
appropriated.� The director shall annually distribute monies in the fund.

B.
Subject to legislative
appropriation or the award of federal grants, or a combination of
APPROPRIATIONS and grants, in an amount of at least $5,000,000 for the purposes
of childhood cancer and rare childhood disease research,
the director
shall allocate monies from the fund
to health care providers and
research institutions that are located in this state, that are nonprofit
organizations and that are engaged in phase I clinical trials relating to
research on pediatric cancer or other rare pediatric diseases.� The monies may
be used in a collaborative study or research program with other facilities
outside of this state. Nonprofit organizations receiving monies from
the fund shall use the monies for the purposes prescribed in this subsection even
if the monies are aggregated with other monies
for the
grants awarded by the childhood cancer and rare childhood disease research
commission established by section 36-121.01
.
Unless
otherwise specified by the federal grant contract, the director may use up to
four percent of the amount appropriated or granted to cover administrative
costs.

C. If the department does not receive
additional legislative appropriations or federal grants, or a combination of
appropriations and grants, for the purposes of childhood cancer and rare
childhood disease research in an amount of at least $5,000,000, the director
shall allocate monies received pursuant to section 28-2442 to health care
providers and research institutions that are located in this state, that are
nonprofit organizations and that are engaged in clinical trials relating to
research on pediatric cancer or other rare pediatric diseases. The monies may
be used in a collaborative study or research program with other facilities
outside of this state. Nonprofit organizations that receive monies
from the childhood cancer and rare disease research fund shall use the monies
for the purposes prescribed in this subsection even if the monies are
aggregated with other monies.

C.

D.
Monies
in the fund are exempt from the provisions of section 35-190 relating to
lapsing of appropriations.
END_STATUTE

Sec. 2. Title 36, chapter 1, article 1, Arizona
Revised Statutes, is amended by adding section 36-121.01, to read:

START_STATUTE
36-121.01.

Childhood cancer and rare childhood disease research commission;
membership; reimbursement; conflict of interest; annual report

A.
Subject to
the conditions specified in section 36-121, subsection B, the childhood
cancer and rare childhood disease research commission is established consisting
of at least the following members who are appointed by the director:

1. One member who is a survivor of
childhood cancer or a caregiver to individuals who have childhood cancer.

2. One member who is a survivor of a
rare childhood disease or a caregiver to individuals who have rare childhood
diseases.

3. Four health professionals who
practice in the field of either pediatric cancer or rare childhood diseases.

4. One member who represents a
nationwide pediatric cancer advocacy nonprofit organization.

B. Commission members shall serve
five-year terms and shall annually elect a chairperson from the
membership.� Commission members are not eligible to receive compensation but
are eligible for reimbursement of expenses pursuant to title 38, chapter 4,
article 2.

C. The commission shall
:

1. Establish criteria for the
clinical trials that qualify to receive research grants.

2. Oversee the application process
and review applications for the clinical trial research grants to assist the
director in selecting the most credible clinical trials to which to award the
research grants.

3. Ensure that all commission
meetings are open to the public and allow for public testimony.

D. The director shall award grants to
health care providers and research institutions that are located in this state,
that are nonprofit organizations and that are engaged in clinical trials
relating to research on pediatric cancer or other rare pediatric diseases.� The
monies awarded may be used in a collaborative study or research program with
other facilities outside of this state. Nonprofit organizations that
receive monies from the
childhood cancer and rare disease
research fund
established by section 36-121 shall
use the monies for the purposes prescribed in this subsection even if the
monies are aggregated with other monies.

D. Commission members shall recuse
themselves from discussing and voting on any matter in which they have a
conflict of interest. If at any time commission member recusals due to
conflicts of interest cause the commission to no longer have a quorum to take
official action, the director or the director's designee and other department
staff members appointed by the director may act as members of the commission on
any grant application at issue.

E. Not later than August 1, 2027 and
August 1 of each year thereafter, the commission shall submit a report to the
appropriations committees and health and human services committees of the
senate and the house of representatives, or their successor committees,
detailing the number, amounts and recipients of the grants awarded pursuant to
this section, the resulting research and any other relevant information.
END_STATUTE

APPROVED BY THE GOVERNOR JUNE 4, 2026.

FILED IN THE OFFICE OF THE SECRETARY OF STATE JUNE 5, 2026.